1209780-71-1

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 3,3-difluoro-4-hydroxy-, 1,1-diMethylethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 3,3-difluoro-4-hydroxy-, 1,1-diMethylethyl ester;1-Boc-3,3-difluoro-4-hydr...;tert-butyl 3,3-difluoro-4-hydroxypiperidine-1-carboxylate;1-Boc-3,3-difluoro-4-hydroxypiperidine;3,3-Difluoro-4-hydroxy-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
• CAS NO: 1209780-71-1
• Molecular Formula: C₁₀H₁₇F₂NO₃
• Molecular Weight: 237.2436864
• Mol File: 1209780-71-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 3,3-difluoro-4-hydroxy-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 3,3-difluoro-4-hydroxy-, 1,1-diMethylethyl ester(1209780-71-1)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 3,3-difluoro-4-hydroxy-, 1,1-diMethylethyl ester(1209780-71-1)

Safety Data

• Hazardous Substances Data: 1209780-71-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Teprenone is used as a pharmaceutical agent for its potential anti-aging and protective effects on the skin. It is believed to have antioxidant and anti-inflammatory properties, which may help improve the skin's barrier function and reduce the appearance of fine lines and wrinkles.
Used in Cosmetic and Skincare Industry:
In the cosmetic and skincare industry, teprenone is used as an ingredient in various products for its potential anti-aging and skin-protective properties. It has been investigated for its capacity to protect against UV-induced skin damage and to promote wound healing, making it a valuable component in skincare formulations aimed at maintaining skin health and appearance.
Used in Antioxidant and Anti-Inflammatory Applications:
Teprenone is utilized for its antioxidant and anti-inflammatory properties, which may contribute to the overall health and well-being of the skin. Its potential to reduce inflammation and oxidative stress can be beneficial in the development of skincare products that address various skin concerns, such as aging, sensitivity, and environmental damage.

Upstream product

• 851314-56-2 ethyl 5,5-difluoro-4-hydroxy-1-(phenylmethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate 
• 851314-55-1 ethyl N-[3-(ethyloxy)-2,2-difluoro-3-oxopropyl]-N-(phenylmethyl)-beta-alaninate 
• 1239596-53-2 N-benzyl-3,3-difluoro-4-hydroxypiperidine 
• 1067914-81-1 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1239596-54-3 3,3-difluoropiperidin-4-ol 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 

Downstream Products

• 1215071-17-2 tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate 
• 1334412-95-1 tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylate 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 

Relevant articles and documents

5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER

The present invention discloses 5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The 5-substituted difluoropiperidine compounds, derivatives

SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

The present invention discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The quinazoline compounds, derivatives and pharmaceutically acceptabl

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Bridged Spiro[2.4]heptane Ester Derivatives

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a cata

FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), wherein n and R1 are as defined in the description, their preparation and their pharmaceutically active compounds.

BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES

The present invention relates to bridged spiro[2.4]heptane ester derivatives of formula (I) wherein W, Y, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.